Therapeutic Effects of Famotidine on Chronic Symptomatic Gastritis: Subgroup Analysis from FUTURE Study

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2011 Dec 21

PMID 22183857

Citations 8

Authors

Yoshikazu Kinoshita

Tsutomu Chiba

Affiliations

Soon will be listed here.

Abstract

Background: A therapeutic strategy for symptomatic patients with chronic gastritis has not been established. Gastric acid has been reported to induce a variety of unpleasant abdominal symptoms. We investigated whether the histamine H2 receptor antagonist famotidine attenuated upper abdominal symptoms in patients with chronic gastritis.

Methods: In this multicenter prospective single-arm open-label study, 10,311 patients with a clinical diagnosis of chronic symptomatic gastritis were enrolled and each patient was administered famotidine at 20 mg/day for 4 weeks. The intensity levels of upper abdominal symptoms, epigastralgia, epigastric fullness, and heartburn were evaluated using a face scale (grade 0-4). Abdominal symptom-related quality of life (QOL) impairment was also evaluated, using an Izumo scale before and after famotidine administration. In a subgroup analysis, symptomatic responses in patients diagnosed with functional dyspepsia (FD) according to the Rome III criteria were analyzed.

Results: In 8,460 patients who completed the protocol, famotidine administration significantly attenuated epigastralgia, epigastric fullness, and heartburn, and famotidine also attenuated abdominal symptom-related QOL impairment in all patients with chronic symptomatic gastritis, in those with FD-like symptoms without organic disease, and in those with FD as defined by the Rome III criteria.

Conclusion: Famotidine is effective to relieve abdominal symptoms and improve QOL, not only in patients with Rome III-defined FD, but also in those with chronic symptomatic gastritis.

Citing Articles

Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China.

Yang Y, Li K, Xu G, Wang C, Xiong H, Wang X World J Gastroenterol. 2024; 30(9):1108-1120.

PMID: 38577179 PMC: 10989489. DOI: 10.3748/wjg.v30.i9.1108.

Gut Frailty: Its Concept and Pathogenesis.

Naito Y Digestion. 2023; 105(1):49-57.

PMID: 37967548 PMC: 10777716. DOI: 10.1159/000534733.

Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus.

Fujishiro M, Kushiyama A, Yamazaki H, Kaneko S, Koketsu Y, Yamamotoya T World J Gastroenterol. 2017; 23(36):6694-6704.

PMID: 29085214 PMC: 5643290. DOI: 10.3748/wjg.v23.i36.6694.

Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.

Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Kobayashi Y, Lefor A Biomed Rep. 2017; 7(3):231-235.

PMID: 28894571 PMC: 5582580. DOI: 10.3892/br.2017.947.

Small Intestinal Bacterial Overgrowth in Patients with Refractory Functional Gastrointestinal Disorders.

Shimura S, Ishimura N, Mikami H, Okimoto E, Uno G, Tamagawa Y J Neurogastroenterol Motil. 2015; 22(1):60-8.

PMID: 26554916 PMC: 4699722. DOI: 10.5056/jnm15116.

References

Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K . Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009; 104(11):2779-87. DOI: 10.1038/ajg.2009.427. View

Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J . Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003; 98(4):783-8. DOI: 10.1111/j.1572-0241.2003.07389.x. View

Mason J, Delaney B, Moayyedi P, Thomas M, Walt R . Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales. Aliment Pharmacol Ther. 2005; 21(9):1135-43. DOI: 10.1111/j.1365-2036.2005.02445.x. View

Kinoshita Y, Chiba T . Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: based on the large-scale survey, FUTURE study. Intern Med. 2011; 50(20):2269-76. DOI: 10.2169/internalmedicine.50.5678. View

Miwa H, Hirai S, Nagahara A, Murai T, Nishira T, Kikuchi S . Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2000; 14(3):317-24. DOI: 10.1046/j.1365-2036.2000.00706.x. View

Tanimura T, Adachi K, Furuta K, Ohara S, Morita T, Koshino K . Usefulness of catheterless radiotelemetry pH monitoring system to examine the relationship between duodenal acidity and upper gastrointestinal symptoms. J Gastroenterol Hepatol. 2010; 26(1):98-103. DOI: 10.1111/j.1440-1746.2010.06468.x. View

Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J . Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998; 115(6):1346-52. DOI: 10.1016/s0016-5085(98)70012-5. View

Seno H, Nakase H, Chiba T . Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther. 2005; 21 Suppl 2:32-6. DOI: 10.1111/j.1365-2036.2005.02471.x. View

Lee K, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J . A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004; 99(9):1765-73. DOI: 10.1111/j.1572-0241.2004.30822.x. View

10.

Kato M, Watanabe M, Konishi S, Kudo M, Konno J, Meguro T . Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther. 2005; 21 Suppl 2:27-31. DOI: 10.1111/j.1365-2036.2005.02470.x. View

11.

Veldhuyzen Van Zanten S, Armstrong D, Chiba N, Flook N, White R, Chakraborty B . Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol. 2006; 101(9):2096-106. DOI: 10.1111/j.1572-0241.2006.00751.x. View

12.

Miwa H, Osada T, Nagahara A, Ohkusa T, Hojo M, Tomita T . Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol. 2006; 21(12):1826-31. DOI: 10.1111/j.1440-1746.2006.04446.x. View

13.

Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada J . Functional gastroduodenal disorders. Gastroenterology. 2006; 130(5):1466-79. DOI: 10.1053/j.gastro.2005.11.059. View

14.

Ikenberry S, Harrison M, Lichtenstein D, Dominitz J, Anderson M, Jagannath S . The role of endoscopy in dyspepsia. Gastrointest Endosc. 2007; 66(6):1071-5. DOI: 10.1016/j.gie.2007.07.007. View

15.

Kamada T, Haruma K, Hata J, Kusunoki H, Sasaki A, Ito M . The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther. 2003; 18(2):245-52. DOI: 10.1046/j.1365-2036.2003.01669.x. View

16.

Hallerback B, Bommelaer G, Bredberg E, Campbell M, Hellblom M, Lauritsen K . Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther. 2002; 16(5):959-67. DOI: 10.1046/j.1365-2036.2002.01236.x. View

17.

Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M . Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2001; (1):CD002096. DOI: 10.1002/14651858.CD002096. View

18.

Talley N, Tack J, Ptak T, Gupta R, Giguere M . Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2007; 57(6):740-6. DOI: 10.1136/gut.2007.132449. View

19.

Quartero A, de Wit N, Lodder A, Numans M, Smout A, Hoes A . Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci. 1998; 43(9):2028-33. DOI: 10.1023/a:1018803129779. View

20.

Kinoshita Y, Hashimoto T, Kawamura A, Yuki M, Amano K, Sato H . Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther. 2005; 21 Suppl 2:37-41. DOI: 10.1111/j.1365-2036.2005.02472.x. View